Navigation Links
GenVec Reports Inducement Award

GAITHERSBURG, Md., May 25, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer.  The option grant was approved by the Compensation Committee of GenVec's Board of Directors and the Board of Directors, and was made as an inducement material to Ms. Collins's acceptance of employment with GenVec in accordance with NASDAQ Listing Rule 5635(c)(4).

The option allows for the purchase of up to 250,000 shares of GenVec's common stock at an exercise price per share equal to $2.54, the closing price of the Company's common stock on May 23, 2012.  The option has a ten-year term and will vest and become exercisable as to one-eighth (1/8th) of the shares of common stock covered by the option on the six month anniversary of the grant date and, on the first day of each month thereafter, the option will vest and become exercisable as to an additional one-forty-eighth (1/48th) of the shares of common stock covered by the option until the option is fully exercisable.

On May 24, 2012, GenVec filed a Form 8-K regarding the appointment of Ms. Collins and related matters.  Please refer to that filing for a full description of the inducement award agreement pursuant to which the option was granted.  GenVec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at and in the Company's various filings with the Securities and Exchange Commission.

Retail Investor and Media Contact:     

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Appoints Cynthia Collins as President and CEO
2. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
3. GenVec to Release Fourth Quarter and Year-End 2011 Financial Results and Conduct a Conference Call on March 15, 2012
4. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
5. GenVec Extends Research Collaboration with Global Pharmaceutical Company
6. GenVec Reports Third Quarter 2011 Financial Results
7. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011
8. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
9. GenVec Reports Second Quarter 2011 Financial Results
10. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
11. GenVec to Host First Quarter 2011 Earnings Call and Webcast
Post Your Comments:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):